SecBot SecBot
424B5 ·Filed Jul 30, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-326370
Notable filing: 424B5
Actionable Insight ▼ Bearish

The offering closes July 31, 2026, creating near-term overhang from the discounted placement and warrant overhang. The key catalyst is the October 30 PDUFA for INO-3107; failure to secure accelerated approval would likely force further dilutive financing or a strategic alternative. Monitor for FDA feedback on accelerated approval eligibility and any updates on the shareholder litigation.

DirectionBearish
Confidencehigh
Horizonweeks

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this 424B5
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.6770
T+0 close · Jul 30, 2026 · via day close
Latest settled
+28.48%
T+60 · $0.8698
Vs SPY
+26.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $0.6770entry
  2. T+1 · 4mo ago +2.92%α +1.50% · $0.6968
  3. T+5 · 3mo ago −1.33%α −4.84% · $0.6680
  4. T+20 · 3mo ago +90.55%α +87.56% · $1.29
  5. T+60 · 22d ago +28.48%α +26.02% · $0.8698
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selling 21.1M shares and warrants for 42.1M shares at $0.95/unit (a ~8% discount to the $1.03 close). The company also disclosed a going-concern risk, preliminary cash of $36.7M as of June 30, 2026, and that the FDA has not yet ruled on INO-3107's accelerated approval eligibility ahead of the October 30 PDUFA date. This offering adds ~30% immediate dilution from shares alone, with potential for further dilution from the 2:1 warrant coverage.

Key Facts

  • Offering of 21,052,632 shares and warrants for 42,105,264 shares at $0.95/unit, raising ~$18.3M net ($20M gross)
  • Warrants exercisable at $1.10/share for 5 years; no public market expected for warrants
  • Pro forma as-adjusted net tangible book value per share of $0.58 vs. offering price of $0.95 = $0.37 immediate dilution per share
  • Company discloses 'substantial doubt exists as to our ability to continue as a going concern'
  • Preliminary cash and cash equivalents of ~$36.7M as of June 30, 2026
  • PDUFA target date for INO-3107 BLA is October 30, 2026; FDA has not provided feedback on accelerated approval eligibility
  • Shareholder class action (Feb 2026) and three derivative lawsuits filed against the company and officers
  • Proceeds intended for potential commercial launch of INO-3107, confirmatory trial, pipeline development, and general corporate purposes

Financial Impact

Immediate dilution of ~30% from shares (21.1M new shares on ~69.8M pre-offering outstanding), plus potential additional dilution from 42.1M warrants (2:1 ratio) at $1.10 exercise price. Net proceeds of ~$18.3M extend runway into late Q1 2027 per management.

dilutioncash runwayshare count

Risk Factors

  • FDA may deny accelerated approval for INO-3107, requiring a costly Phase 3 trial or alternative path
  • Warrant exercise at $1.10 (above current $1.03 price) is unlikely near-term, but cashless exercise could still add dilution
  • Going-concern risk if capital is insufficient to fund operations through potential launch
  • Shareholder class action and derivative lawsuits could result in material damages or management distraction
  • Frequent capital raises (12 filings in 24 months) signal ongoing cash burn and potential for further dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-326370
Document: 0001193125-26-326370-index-headers.html0001193125-26-326370
Document: 0001193125-26-326370-index.html0001193125-26-326370
Document: 0001193125-26-326370.txt0001193125-26-326370

Track record

20 reports on INO

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026